Skip to main content
Top
Published in: Clinical and Experimental Nephrology 5/2013

01-10-2013 | Review Article

Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides

Author: J. Charles Jennette

Published in: Clinical and Experimental Nephrology | Issue 5/2013

Login to get access

Abstract

The nomenclature and classification of vasculitis has been difficult and controversial for many decades. This is problematic both for research on vasculitis as well as clinical care of patients with vasculitis. The first (1994) International Chapel Hill Consensus Conference on the Nomenclature of Systemic Vasculitides (CHCC) proposed names and definitions for the most common forms of vasculitis. Since then, there have been substantial advances in our understanding of vasculitis and changes in medical terminology. In addition, CHCC 1994 did not propose a nomenclature for some relatively common forms of vasculitis, such as vasculitis secondary to other diseases. To address these issues, a second International Chapel Hill Consensus Conference was held in 2012. The goals were to change names and definitions as appropriate, and add important categories of vasculitis not included in CHCC 1994. This overview summarizes the 2012 CHCC and points out the changes compared to the 1994 CHCC. Notable changes include the introduction of new terms such as granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis and immunoglobulin A vasculitis and the inclusion of categories for variable vessel vasculitis and secondary forms of vasculitis.
Literature
1.
go back to reference Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CGM, McCluskey RT, Sinico RA, Rees AJ, van Es LA, Waldherr R, Wiik A. Nomenclature of systemic vasculitides: the proposal of an international consensus conference. Arthritis Rheum. 1994;37:187–92.PubMedCrossRef Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CGM, McCluskey RT, Sinico RA, Rees AJ, van Es LA, Waldherr R, Wiik A. Nomenclature of systemic vasculitides: the proposal of an international consensus conference. Arthritis Rheum. 1994;37:187–92.PubMedCrossRef
2.
go back to reference Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CGM, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DGI, Specks U, Stone JH, Takahashi K, Watts RA. 2012 Revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65:1–11.PubMedCrossRef Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CGM, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DGI, Specks U, Stone JH, Takahashi K, Watts RA. 2012 Revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65:1–11.PubMedCrossRef
3.
go back to reference Guillevin L, Lhote F, Amouroux J, Gherardi R, Callard P, Casassus P. Antineutrophil cytoplasmic antibodies, abnormal angiograms and pathological findings in polyarteritis nodosa and Churg–Strauss syndrome: indications for the classification of vasculitides of the polyarteritis Nodosa Group. Br J Rheumatol. 1996;35:958–64.PubMedCrossRef Guillevin L, Lhote F, Amouroux J, Gherardi R, Callard P, Casassus P. Antineutrophil cytoplasmic antibodies, abnormal angiograms and pathological findings in polyarteritis nodosa and Churg–Strauss syndrome: indications for the classification of vasculitides of the polyarteritis Nodosa Group. Br J Rheumatol. 1996;35:958–64.PubMedCrossRef
4.
go back to reference Jennette JC, Falk RJ, Hu P, Xiao H. Pathogenesis of anti-neutrophil cytoplasmic autoantibody associated small vessel vasculitis. Annu Rev Pathol Mech Dis. 2013;8:139–60.CrossRef Jennette JC, Falk RJ, Hu P, Xiao H. Pathogenesis of anti-neutrophil cytoplasmic autoantibody associated small vessel vasculitis. Annu Rev Pathol Mech Dis. 2013;8:139–60.CrossRef
5.
go back to reference Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR, Baslund B, Brenchley P, Bruchfeld A, Chaudhry AN, Cohen Tervaert JW, Deloukas P, Feighery C, Gross WL, Guillevin L, Gunnarsson I, Harper L, Hrušková Z, Little MA, Martorana D, Neumann T, Ohlsson S, Padmanabhan S, Pusey CD, Salama AD, Sanders JS, Savage CO, Segelmark M, Stegeman CA, Tesař V, Vaglio A, Wieczorek S, Wilde B, Zwerina J, Rees AJ, Clayton DG, Smith KG. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012;367:214–23.PubMedCrossRef Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR, Baslund B, Brenchley P, Bruchfeld A, Chaudhry AN, Cohen Tervaert JW, Deloukas P, Feighery C, Gross WL, Guillevin L, Gunnarsson I, Harper L, Hrušková Z, Little MA, Martorana D, Neumann T, Ohlsson S, Padmanabhan S, Pusey CD, Salama AD, Sanders JS, Savage CO, Segelmark M, Stegeman CA, Tesař V, Vaglio A, Wieczorek S, Wilde B, Zwerina J, Rees AJ, Clayton DG, Smith KG. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012;367:214–23.PubMedCrossRef
6.
go back to reference Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior JBA, Jennette CE, Nachman PH, Jennette JC, Falk RJ. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum. 2012;64:3452–62.PubMedCrossRef Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior JBA, Jennette CE, Nachman PH, Jennette JC, Falk RJ. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum. 2012;64:3452–62.PubMedCrossRef
7.
go back to reference Falk RJ, Gross WL, Guillevin L, Hoffman G, Jayne DRW, Jennette JC, et al. “Granulomatosis with polyangiitis (Wegener’s)”: an alternative name for “Wegener’s granulomatosis”. A joint proposal of the American College of Rheumatology, the American Society of Nephrology, and the European League Against Rheumatism. Ann Rheum Dis. 2011;70:704.PubMedCrossRef Falk RJ, Gross WL, Guillevin L, Hoffman G, Jayne DRW, Jennette JC, et al. “Granulomatosis with polyangiitis (Wegener’s)”: an alternative name for “Wegener’s granulomatosis”. A joint proposal of the American College of Rheumatology, the American Society of Nephrology, and the European League Against Rheumatism. Ann Rheum Dis. 2011;70:704.PubMedCrossRef
8.
go back to reference Falk RJ, Gross WL, Guillevin L, Hoffman G, Jayne DRW, Jennette JC, et al. “Granulomatosis with polyangiitis (Wegener’s)”: an alternative name for “Wegener’s granulomatosis”. A joint proposal of the American College of Rheumatology, the American Society of Nephrology, and the European League Against Rheumatism. J Am Soc Nephrol. 2011;22:587–8.PubMedCrossRef Falk RJ, Gross WL, Guillevin L, Hoffman G, Jayne DRW, Jennette JC, et al. “Granulomatosis with polyangiitis (Wegener’s)”: an alternative name for “Wegener’s granulomatosis”. A joint proposal of the American College of Rheumatology, the American Society of Nephrology, and the European League Against Rheumatism. J Am Soc Nephrol. 2011;22:587–8.PubMedCrossRef
9.
go back to reference Falk RJ, Gross WL, Guillevin L, Hoffman G, Jayne DRW, Jennette JC, et al. “Granulomatosis with polyangiitis (Wegener’s)”: an alternative name for “Wegener’s granulomatosis”. A joint proposal of the American College of Rheumatology, the American Society of Nephrology, and the European League Against Rheumatism. Arthritis Rheum. 2011;63:863–4.PubMedCrossRef Falk RJ, Gross WL, Guillevin L, Hoffman G, Jayne DRW, Jennette JC, et al. “Granulomatosis with polyangiitis (Wegener’s)”: an alternative name for “Wegener’s granulomatosis”. A joint proposal of the American College of Rheumatology, the American Society of Nephrology, and the European League Against Rheumatism. Arthritis Rheum. 2011;63:863–4.PubMedCrossRef
10.
go back to reference Sinico RA, Di Toma L, Maggiore U, Tosoni C, Bottero P, Sabadini E, et al. Renal involvement in Churg-Strauss syndrome. Am J Kidney Dis. 2006;47:770–9.PubMedCrossRef Sinico RA, Di Toma L, Maggiore U, Tosoni C, Bottero P, Sabadini E, et al. Renal involvement in Churg-Strauss syndrome. Am J Kidney Dis. 2006;47:770–9.PubMedCrossRef
11.
go back to reference Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011;22:1795–803.PubMedCrossRef Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011;22:1795–803.PubMedCrossRef
Metadata
Title
Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides
Author
J. Charles Jennette
Publication date
01-10-2013
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 5/2013
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-013-0869-6

Other articles of this Issue 5/2013

Clinical and Experimental Nephrology 5/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.